We evaluated whether ER/PR/HER2 subtype and TNM stage of invasive breast carcinoma had a significant impact on overall survival in a cohort of 232 elderly Caucasian female patients (≥70 y/o) from our institution over a 10 year interval (January 1998–July 2008), with at least a subsequent 60 month follow-up period (median follow up 72 months). The gene discussed is ERBB2; the disease is invasive breast carcinoma.